Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2025-12-24 @ 5:58 PM
Study NCT ID:
NCT04172168
Status:
UNKNOWN
Last Update Posted:
2021-04-01
First Post:
2019-11-18
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Left Ventricular Free-wall Ruptrue After Acute Myocardial Infarction (LVFR-AMI)
Sponsor:
Xiamen Cardiovascular Hospital, Xiamen University
Organization:
Study Overview
Official Title:
Clinical Characteristics of Left Ventricular Free-wall Ruptrue After Acute Myocardial Infarction
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Left Ventricular Free-wall Ruptrue (LVFR) is a serious complication caused high mortality.
Detailed Description:
The actual mortality of LVFR is close to 100%. Despite the mortality rate for LVFR has been decreasing with the development of reperfusion therapy, the serious complication remains a difficult challenge. The coronary anatomy distribution associated with LVFR has an interesting phenomenon. From the perspective of different coronary distribution, we can better known the risk factors related to LVFR.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: